---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-291352"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2025-11-21T23:59:59+00:00"
generated_at: "2026-05-16T17:42:50.119224+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# K2HV converts $2.5M loan principal into 2.85M NMRA shares at $0.8774/share

## Summary
- K2 HealthVentures converted $2.5M of term-loan principal into 2,849,327 common shares of NMRA at $0.8774/share.
- Conversion was exercised under loan agreement dated May 9, 2025, as amended November 4, 2025.
- Shares were issued in reliance on Section 4(a)(2) exemption from registration.
- Total conversion right under loan agreement remains up to $12.5M; $10M principal remains convertible.

## SEC filing metadata
- accession: 0001193125-25-291352
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2025-11-21T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312525291352/0001193125-25-291352-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312525291352/d873320d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-291352
- JSON: https://secwatch.observer/filing/0001193125-25-291352.json
- Plain text: https://secwatch.observer/filing/0001193125-25-291352.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.